Gala Pharmaceutical Inc. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues
Gala Pharmaceutical Inc. reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues of $383.00 thousand for the 6-month period ending 2019-05-31, per its 10-Q filed 2019-07-23.
Discontinued › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases, Sales, Issues, Settlements
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues · last filed 2019-07-23
- Gala Pharmaceutical Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, issues for the quarter ending 2019-05-31 was $48.26K.
- Gala Pharmaceutical Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, issues for the quarter ending 2019-02-28 was $334.74K.
- Gala Pharmaceutical Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, issues for fiscal 2018 was $122.11K.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues 3 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues 6 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues 12 month |
|---|---|---|---|
| 2019-05-31 | $48.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-23 | $383.00K 10-Q · filed 2019-07-23 | |
| 2019-02-28 | $334.74K 10-Q · filed 2019-04-30 | ||
| 2018-11-30 | $122.11K 10-K · filed 2019-04-15 |